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A B S T R A C T   
Machado-Joseph disease (MJD/SCA3) is a neurodegenerative polyglutamine disorder exhibiting a wide spectrum 
of phenotypes. The abnormal size of the (CAG)n at ATXN3 explains ~55% of the age at onset variance, sug-
gesting the involvement of other factors, namely genetic modifiers, whose identification remains limited. Our 
aim was to find novel genetic modifiers, analyse their epistatic effects and identify disease-modifying pathways 
contributing to MJD variable expressivity. We performed whole-exome sequencing in a discovery sample of four 
age at onset concordant and four discordant first-degree relative pairs of Azorean patients, to identify candidate 
variants which genotypes differed for each discordant pair but were shared in each concordant pair. Variants 
identified by this approach were then tested in an independent multi-origin cohort of 282 MJD patients. Whole- 
exome sequencing identified 233 candidate variants, from which 82 variants in 53 genes were prioritized for 
downstream analysis. Eighteen disease-modifying pathways were identified; two of the most enriched pathways 
were relevant for the nervous system, namely the neuregulin signaling and the agrin interactions at neuro-
muscular junction. Variants at PARD3, NFKB1, CHD5, ACTG1, CFAP57, DLGAP2, ITGB1, DIDO1 and CERS4 
modulate age at onset in MJD, with those identified in CFAP57, ACTG1 and DIDO1 showing consistent effects 
across cohorts of different geographical origins. Network analyses of the nine novel MJD modifiers highlighted 
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several important molecular interactions, including genes/proteins previously related with MJD pathogenesis, 
namely between ACTG1/APOE and VCP/ITGB1. We describe novel pathways, modifiers, and their interaction 
partners, providing a broad molecular portrait of age at onset modulation to be further exploited as new disease- 
modifying targets for MJD and related diseases.   
1. Introduction 
Variable expressivity, namely in age at onset (AO) of symptoms is a 
hallmark of polyglutamine (polyQ) disorders, a group of genetically 
determined late-onset neurodegenerative diseases including Huntington 
disease and the most common dominant ataxias (spinocerebellar ataxias 
SCA1, SCA2, SCA3, SCA6, SCA7 and SCA17). At each of these disease 
loci, exonic CAG repeats beyond a critical threshold cause disease 
(reviewed in Gatchel and Zoghbi (2005)). The number of repeat units in 
the expanded allele, however, only partially correlates with AO (Gusella 
et al., 2014; Chen et al., 2018). This incomplete correlation, observed in 
variable degree in all polyQ disorders, suggests the involvement of 
modifying factors, namely genetic. Evidence so far seems to indicate that 
such genetic modifiers operate in a highly complex system of small to 
moderate effects of multiple modifier genes, which interact together and 
with environmental factors, resembling a polygenic disease (Gusella 
et al., 2014; Chen et al., 2018; Génin et al., 2008). 
Machado-Joseph disease/spinocerebellar ataxia type 3 (MJD/SCA3) 
is the most frequent dominant ataxia worldwide; it displays a wide 
variability in AO (average of ~40 years; range from 4 to 78 years) 
(Carvalho et al., 2008; Tezenas du Montcel et al., 2014; Raposo et al., 
2015), only about 55% of which is explained by size of the (CAG)n tract 
length (de Mattos et al., 2019). An expanded polyglutamine tract 
consensually exceeding 51 repeats (reviewed in Bettencourt and Lima 
(2011)), triggers disease through a cascade of pathological events, 
leading to neuronal dysfunction and loss (reviewed in Da Silva et al. 
(2019)). MJD remains untreatable and the discovery of disease- 
modifying genes may pinpoint novel molecular targets for drug devel-
opment. Moreover, the identification of such modifiers should allow a 
better prediction of AO, providing useful information for genetic coun-
selling and patient stratification for clinical trials design. Previous at-
tempts have used mostly candidate gene approaches, proposing as 
disease modifiers the size of repeats at other (CAG)n disease loci 
(Tezenas du Montcel et al., 2014); Raposo et al., 2015; Jardim et al., 
2003, allelic variants at the apolipoprotein E (APOE) locus (Bettencourt 
et al., 2011; Peng et al., 2014) or in DNA repair genes (Bettencourt et al., 
2016; Mergener et al., 2020). Difficulties in replication, however, are 
widely acknowledged and attributed to sample size, study design or 
population-specific allelic frequencies at the candidate loci (Chen et al., 
2018; Raposo et al., 2015). Unbiased genome-wide association studies 
(GWAS) may circumvent some of these constrain, allowing the simul-
taneous identification of several modifier variants and their interactions 
(Petersen et al., 2017), as well as point to modifying pathways. Recently, 
a large GWAS suggested nine associated loci as AO modifiers of MJD, 
explaining 8% of AO variance (Akçimen et al., 2020). Nevertheless, a 
considerable part of AO variance remained unanswered and disease- 
modifying pathways remain to be clarified. 
The context of the Azores islands (Portugal), where MJD reaches the 
highest known prevalence worldwide (de Araújo et al., 2016), provides 
important advantages for the quest for novel modifiers, including a more 
homogeneous genetic background is expected, since the islands had a 
limited number of founders and were subjected to some degree of 
geographical isolation (Santos et al., 2003; Montiel et al., 2005). 
Furthermore, extended genealogies of the local MJD families (Lima 
et al., 1997; Lima et al., 1998), coupled with the regular follow-up of 
patients for over 20 years, should empower studies using this cohort. 
As in other monogenic diseases (e.g., Rahit and Tarailo-Graovac, 
2020), major gaps remain in the identification and understanding of 
genetic modifiers in MJD. Thus, we obtained unbiased whole-exome 
sequencing (WES) data from pairs of first-degree relative patients, 
who were highly discordant for AO and then compared with AO- 
concordant pairs from the same family, proposing a robust criterium 
to filter putative modifier genes. We further investigated modifier effects 
of the candidate WES variants using genotype-phenotype correlations in 
four distinct validation cohorts. 
2. Materials and methods 
2.1. Patients and samples 
Genomic DNA from blood samples of a total of 282 MJD patients was 
used. All participants were clinically and molecularly confirmed to be 
MJD patients; sizing of the CAG tract at ATXN3 locus (normal allele - 
CAGN and expanded allele - CAGE) was performed for all cohorts at a 
single laboratory, which routinely performs the molecular test for MJD. 
Age at onset (AO) was defined as the age at manifestation of the first gait 
disturbances, reported by the patient or a close relative/caregiver. 
2.1.1. Discovery sample 
WES was performed in samples from 16 Azorean patients: four AO- 
discordant and four AO-concordant affected first-degree pairs selected 
from extended Azorean MJD pedigrees. For each discordant pair, a 
concordant pair was selected from the same extended kindred. Patients 
of discordant pairs had a mean AO difference of 9 years (range: 7–11 
years), whereas concordant pairs showed a mean AO difference of 2 
years (range: 1–4 years). The discovery sample is described in Suppl. 
Table 1. Each affected pair, both concordant and discordant, had an 
equal (CAG)n size (±1 repeat) in the expanded allele. 
2.1.2. Validation cohorts 
for genotype-phenotype correlations, several MJD cohorts were 
used: 103 Azorean patients, including the 16 patients analysed by WES; 
72 patients from mainland Portugal; 78 patients from Brazil; and an 
additional cohort of 29 patients from the UK (of multi-ethnic back-
ground). Characterization of the four validation cohorts is shown in 
Table 1. 
The study design is summarized in Fig. 1. 
2.2. WES analysis of the discovery sample 
WES was performed at Macrogen, Inc. (Suppl. Mat.) for all samples of 
the discovery sample (Fig. 1A); samples yielded 6.9 to 13.1 GB of high- 
quality aligned data. Mean target coverage ranged 56.06× to 93.35×, 
with 91.0%–98.3% being covered at least 10× and 77% being covered at 
least ≥30× (Suppl. Table 2). A script using R language was used to 
retrieve, from the total list of variants obtained by WES, those variants 
whose genotype differed for each discordant pair, but was the same in 
members of each concordant pair (n = 233 variants - list #1, Fig. 1A, 
Suppl. Table 3). Next, only variants in genes expressed in brain tissues, 
including cerebellum (expression data were accessed from the GTEx 
project; 24) were considered for further analysis (n = 184 variants – list 
#2, Fig. 1B, Suppl. Table 3). Exonic variants were sorted by type of 
mutation, prioritizing nonsense, frameshift, and missense variants. 
Using information of the Human Splicing Finder (Desmet et al., 2009), 
intronic and synonymous variants were ranked by potential impact on 
splicing. The final list (list #3) contained 82 variants, located in 53 genes 
(Suppl. Table 3 & 4): one frameshift, 18 missense, one splice-acceptor, 
43 intronic and 19 synonymous (Fig. 1B), which were successfully 




Demographic, genetic, and clinical features for MJD patients. (a) patients were grouped by geographical origin and (b) pooled Azorean islands and mainland Portuguese patients (=Portuguese cohort), as well as 
Portuguese (Azorean and mainland Portugal) and Brazilian patients pooled together (=pooled Portuguese-Brazilian cohort).  
a. 
Azorean Islanders1, n ¼ 103 Mainland Portuguese2, n ¼ 72 
Gender 52F|51M 



















CAGN 21.1 ± 4.8 CAGN 22.7 ± 6.7 
CAGE 71.5 ± 3.7 CAGE 70.7 ± 3.8 
rAO 37.5 ± 11.8 rAO 41.4 ± 13.1 
eAO 36.7 ± 0.8 eAO 38.6 ± 0.9 
rlinear − 0.807 rlinear − 0.818 
rquadratic − 0.807 rquadratic − 0.822 
r2linear 0.651 r2linear 0.669 
r2quadratic 0.651 r2quadratic 0.675  
Brazilians, n ¼ 78 Multi-ethnic sample3, n ¼ 29 
Gender 39F|39M 



















CAGN 22.5 ± 4.6 CAGN 21.1 ± 6.1 
CAGE 73.9 ± 3.4 CAGE 70.5 ± 5.2 
rAO 34.3 ± 11.2 rAO 35.0 ± 11.4 
eAO 39.4 ± 0.9 eAO – 
rlinear − 0.707 rlinear − 0.684 
rquadratic − 0.709 rquadratic − 0.703 
r2linear 0.501 r2linear 0.468 
r2quadratic 0.502 r2quadratic 0.494   
b. 
Portuguese cohort, n ¼ 175 Pooled Portuguese-Brazilian cohort2, N ¼ 253 
Gender 81F|91M 



















CAGN 21.8 ± 5.7 CAGN 22.0 ± 5.4 
CAGE 71.2 ± 3.7 CAGE 72.0 ± 3.8 
rAO 39.1 ± 12.4 rAO 37.7 ± 12.2 
eAO – eAO – 
rlinear − 0.813 rlinear − 0.787 
rquadratic − 0.814 rquadratic − 0.787 
r2linear 0.662 r2linear 0.619 
r2quadratic 0.662 r2quadratic 0.620 
All continuous variables are shown as mean ± standard deviation (SD), excluding the AOa which is shown as mean ± standard error (SE); 1includes Azorean patients from discovery cohort; 2 gender for three patients is 
missing; 3gender for two patients is missing; CAGN = number of CAG repeats in the normal allele; CAGE = number of CAG repeats in the expanded allele; rAO = age at onset (AO) was considered as the age of manifestation 
of gait disturbances, reported by the patient or a close relative; eAO = adjusted AO calculated using the population of origin as a fixed factor and the covariate appearing in the model are evaluated at CAGE = 72; AO of 
Brazilian cohort is different from Mainland Portugal cohort and from pooled Portuguese cohort. CAGE of Brazilian cohort is different from Azorean, mainland Portuguese, multi-ethnic sample and from Portuguese. All tests 
were performed by an Anova, Tukey HSD p < 0.05. 
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genotyped in the validation cohorts. 
2.3. Multiplexed sequencing and data analysis of the discovery sample 
and validation cohorts 
Candidate variants (n = 82) were genotyped (Suppl. Mat.) at Euro-
fins Genomics (www.eurofinsgenomics.eu), in 282 samples from the 
validation cohorts (Fig. 1C). 
Determination of allelic and genotypic frequencies, conformity with 
the Hardy-Weinberg equilibrium and linkage disequilibrium were ob-
tained in FSTAT (Goudet, 2002) and GENEPOP (Rousset, 2008). More-
over, allelic and genotypic frequencies in samples from Azores, 
Mainland Portugal, Brazil and the multi-ethnic cohort were used to 
perform an exact test of population differentiation (data available upon 
request). 
Independent main effects and gene-gene interactions of allelic vari-
ants on MJD AO were tested using parametric (ANCOVA) and 
nonparametric (Multifactor Dimensionality Reduction) analyses. 
An ANCOVA, using the CAGE as covariate, was performed to calcu-
late and compare adjusted AO (=adjAO) between genotypes. As no 
differences in the distribution of AO and in CAGE, as well as no differ-
ences in genotypic/allelic frequencies of the 82 variants were observed 
between patients from Azores and mainland Portugal (ANOVA, Tukey 
HSD p > 0.05), these cohorts were pooled together for the analyses 
(=Portuguese cohort). A pooled Portuguese-Brazilian cohort was also 
analysed, using size of CAGE and geographical origin as covariates. To 
warrant those comparisons were made between genotypic classes with 
similar number of samples we (1) clustered two genotypic classes, 
comparing REF|REF versus REF|VAR + VAR|VAR; or (2) excluded the 
genotypic class with lower number of samples and compared REF|VAR 
versus VAR|VAR (REF = reference sequence and VAR = variant 
sequence). 
Nonlinear gene-gene interactions were detected by the Multifactor 
Dimensionality Reduction (MDR) software 3.0.2 (Hahn et al., 2003), 
using default settings. Cross-validation consistency (CVC), a measure of 
how often the best model is found across the different tenfold cross- 
validation interval was calculated; a higher CVC indicates a more 
consistent result (Hahn et al., 2003). Genotypes for each variant and 
CAGE were used as attributes, and AO as the outcome. 
Statistical analyses were performed in IBM SPSS Statistics 22 (IBM 
Corp. Released 2013) and GraphPad Prism 8.0.1. A P-value below 0.05 
was considered as significant for all tests. 
Pathway and interaction-network analyses were generated by IPA 
(QIAGEN Inc., https://www.qiagenbioinformatics.com/products/i 
ngenuity-pathway-analysis; (Krämer et al., 2014)). An interaction 
network between ATXN3 and candidate modifier genes was explored 
using the Path Explorer tool, which calculated the “Shortest Path” be-
tween 2 molecules. ATXN3 interactors with no links with at least one 
candidate modifier were removed. All analyses were run under default 
settings, with exception of the confidence level, which was set to include 
only experimentally observed interactions. For pathway enrichment 
analysis, an FDR adjusted P-value <0.05 was considered significant. 
3. Results 
3.1. WES in affected pairs identifies candidate modifier genes of AO in 
MJD 
We performed WES in a discovery sample of 16 MJD patients, 
grouped as pairs of AO-concordant and discordant first-degree relatives. 
An average of 121,105 variants were identified per patient, of which 
20% were coding variants (Suppl. Table 2). For 233 variants (list #1, 
Fig. 1B; Suppl. Table 3), genotypes differed in the AO-discordant pairs 
and were identical in AO-concordant pairs; 184 variants were prioritized 
for further investigation (list #2, Fig. 1B, Suppl. Table 3). Character-
ization of the 82 candidate variants (list #3, Fig. 1B) successfully gen-
otyped is provided in Suppl. Table 4. 
Gene enrichment analyses, using the 53 unique genes from list #3 
(Suppl. Table 4), resulted in 18 over-represented pathways (Table 2), 
including two nervous system specific pathways: the neuregulin 
signaling (4.3%) and the agrin interactions at neuromuscular junction 
(3.9% of overlapping genes). 
3.2. Single-locus analysis in independent cohorts identifies CFAP57, 
PARD3, CHD5, ACTG1, NFKB1, DLGAP2, ITGB1 and DIDO1 as modifier 
genes of AO in MJD 
Next, we tested the independent main effects of each of the 82 var-
iants on AO in the Portuguese cohort (n = 175). Five variants in five 
genes showed a significant effect (Fig. 2A): a synonymous variant in 
PARD3 (rs11009651), an intronic variant in NFKB1 (rs4648050), an 
intronic variant in CHD5 (rs2273034), a synonymous variant in ACTG1 
(rs1139405) and an intronic variant in CFAP57 (rs2483688). The 
Fig. 1. Flow diagram of the study design. (A) Whole-exome sequencing (WES) 
analyses of AO-discordant and AO-concordant first-degree relative pairs; (B) 
WES variants were selected using two main criteria (brain expression and po-
tential functional impact) to select the most promising for further analyses; (C) 
Analysis of modulatory effects of variants/genes. The identification of all var-
iants (List #1, #2 and #3) is available in Suppl. Table 3. 
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PARD3 variant was associated with an earlier AO, and the remaining 
with later AO (Fig. 2A). The CFAP57 variant explained 4.2% of AO 
variance, followed by PARD3 (3.9%), CHD5 (3%), ACTG1 (2.6%) and 
NFKB1 (2.3%). 
In the Brazilian cohort (n = 78), two variants in two genes impacted 
significantly on AO: an intronic variant at DLGAP2 (rs2293909) and a 
synonymous variant at ITGB1 (rs2298141): the DLGAP2 variant was 
associated with an earlier onset (explaining 10% of AO variance), 
whereas the ITGB1 variant was associated with a later onset (5.3% of 
variance) (Fig. 2B). In this cohort, ACTG1 and CFAP57 maintained the 
same direction of effect as observed in the Portuguese patients, whereas 
PARD3, CHD5 and NFKB1 showed no impact on adjAO. In the Portu-
guese cohort, DLGAP2 and ITGB1 showed an opposite direction of effect, 
compared to the Brazilian cohort. 
To increase statistical power, we pooled the Portuguese and the 
Brazilian cohorts (n = 253); the effects on AO of the two variants at 
ACTG1 and CFAP57 observed in the Portuguese cohort were maintained 
(Fig. 2C); additionally, two other missense variants were confirmed to 
modulate AO in the pooled Portuguese-Brazilian cohorts: V1 
(rs1883848) and V2 (rs1883847), both at DIDO1 (Fig. 2C). DIDO1 var-
iants (V1 and V2), which are not in LD (data not shown) explained an 
additional 1.6% and 2.5% of AO variance, respectively, beyond 
geographical origin and size of CAGE. 
3.3. Multi-locus analysis in independent cohorts confirms NFKB1 and 
identifies CERS4 as modifiers of AO in MJD 
To detect putative nonlinear interaction effects among all 82 vari-
ants, two- and three-loci combinations were obtained after performing 
an exploratory quantitative MDR (qMDR) analysis. In the Portuguese 
cohort, a two-loci interaction model containing CAGE and NFKB1 was 
the best model to predict AO (CVC = 9/10, p < 0.05), confirming also 
the previously described linear independent effect of NFKB1. A two-loci 
model containing CAGE and an intronic variant at CERS4 (which failed 
to show an independent effect on AO in previous analyses) was the best 
model to predict AO (CVC = 8/10, p < 0.05) in the Brazilian cohort. In 
the pooled Portuguese-Brazilian cohorts, the best predictive model of 
AO was the CAGE*ACTG1 variant combination (CVC = 4/10, p > 0.05), 
although not reaching significance. 
3.4. The effects of the variants in CHD5, CFAP57, ITGB1 and DIDO1 
seem to be maintained in a multi-ethnic cohort 
The variants in CHD5, CFAP57, ITGB1 and DIDO1 showed the same 
independent effect trends in an additional multi-ethnic cohort (p > 0.05, 
Suppl. Fig. 1). None of the two-loci combination, namely CAGE*NFKB1 
and CAGE*CERS4, provided a good explanation for AO in this sample. 
Despite the limited statistical power of this analysis (Suppl. Fig. 2), these 
results supported an effect of the CHD5, CFAP57, ITGB1 and DIDO1 
variants on AO across populations of multiple ancestry. 
To determine if allelic frequencies for the ten variants in MJD pa-
tients were similar to those from control populations (non-MJD), com-
parisons between our cohort and non-MJD populations were performed; 
we found that the alternative allele at PARD3 and DIDO1-v2 was more 
frequent in MJD patients then in European or Global populations. 
Contrarily, the frequency of the alternative alleles at CERS4 and at 
ACTG1 was significantly lower in MJD patients compared to Global and 
European populations, respectively. Frequencies for the remaining 
variants were similar between MJD patients and European or Global 
populations. 
3.5. Network analyses revealed direct interactions between ATXN3 and 
NFKB1 
A network analysis was performed by joining ATXN3 and the nine 
confirmed genetic modifiers provided by genotype-phenotype correla-
tions (eight from the single and one from the multi-loci analysis). Several 
biological relationships were found between ATXN3 and the 9 modifier 
genes (Fig. 3; Suppl. Table 5), comprising a total of 200 molecules 
involved in the network. Protein-protein interactions (direct links) were 
observed between ATXN3 and NFKB1. 
We next performed a pathway enrichment analysis, using all mole-
cules from the abovementioned network (n = 200) and found the BAG2 
(Bcl2-associated athanogene 2) signaling pathway with the strongest 
enrichment (− log (B-H p-value) = 24). Furthermore, protein ubiquiti-
nation, Huntington’s Disease signaling, and unfolded protein response 
were also among the more strongly enriched pathways (Suppl. Table 6). 
4. Discussion 
Due to inherent (genetic and non-genetic) confounders, difficulties 
are acknowledged in the identification of common genetic modifiers 
between geographically and ethnically distinct cohorts; such difficulties 
are amplified in rare diseases, such as MJD. In this study, we have used 
an innovative study design, by applying a combination of exome-wide 
screening for variants discovery with a candidate gene approach, to 
identify novel modifiers for MJD. We first performed WES, in a dis-
covery sample of AO-discordant and concordant first-degree relative 
pairs, selected from the relatively homogeneous and well-documented 
Azorean cohort (Raposo et al., 2015; Lima et al., 1997), which 
Table 2 
Eighteen statistically significant canonical pathways were obtained using all 
genes (N = 53) containing variants further analysed in the validation cohorts. 
The -log (Benjamini-Hochberg p-value) greater than 1.3 was considered statis-
tically significant.  
Ingenuity Canonical Pathways Overlap* Molecules 
















Calcium-induced T Lymphocyte Apoptosis 3|60 (5%) ITPR3,HLA-DRA, 
EP300 




TR/RXR Activation 3|100 
(3%) 
MTOR,SREBF2,EP300 
Fcγ Receptor-mediated Phagocytosis in 









Crosstalk between Dendritic Cells and 





HER-2 Signaling in Breast Cancer 3|99 (3%) NRG1,ITGB1,PARD3 




















FAK Signaling 3|109 
(2.8%) 
ITGB1,DOCK1,ACTG1 
ErbB Signaling 3|108 
(2.8%) 
NRG1,MTOR,TGFA  
* Number (percentage) of molecules overlapping with the total number of 
genes belonging to that pathway. 
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allowed us to identify variants with potential effects among the high 
number of variants arising from WES. This discovery step was then 
complemented by testing the impact on AO of the most promising var-
iants in genotype-phenotype correlations using larger and independent 
cohorts of MJD patients. 
We showed that variants at PARD3, NFKB1, CHD5, ACTG1, CFAP57, 
DLGAP2, ITGB1, DIDO1 and CERS4 modifies AO in MJD, with those in 
CFAP57, ACTG1 and DIDO1 having consistent effects across patients 
from different geographical origins. 
From the 18 statistically enriched pathways found, the neuregulin 
signaling and agrin interactions at neuromuscular junction were of 
particular interest, due to their specific function in the nervous system. 
Neuregulin signaling plays diverse roles in the CNS and peripheral 
nervous system, namely in synapse formation, radial neuron migration, 
GABAergic neuron migration, neural crest cells differentiation and 
migration, neuromuscular junction and Schwann cell development, 
maturation, and myelination (Kataria et al., 2019). The neuregulin 
pathway has been linked to processes relevant for neurodegeneration, 
including oxidative stress and neuroinflammation (Xu et al., 2017; Jiang 
et al., 2016). The neuromuscular junction is a chemical synapse that is 
created between motor neurons and skeletal muscles and is covered by 
Schwann cells (Li et al., 2018). The agrin-LRP4-MuSK signaling drives 
Fig. 2. Effect of the candidate variants on adjusted AO (adjAO; mean ± standard error): (A) Portuguese (n = 175); (B) Brazilian (n = 78); and (C) pooled Portuguese- 
Brazilian cohorts (n = 253). The adjAO corresponds to AO statistically adjusted for mean CAGE size in each cohort, i.e. (A) 71, (B) 74 and (C) 72. Number of patients 
by allelic variant/gene are shown inside the bars. Dashed line represents the average AO of each respective cohort. Only variants showing statistically significant 
differences are displayed (p < 0.05). 
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the aggregation of acetylcholine receptors and guarantees efficient 
signal transduction at the neuromuscular junction (Ohno et al., 2017). 
This ultimately leads to the initiation of muscle contraction, making the 
neuromuscular junction essential for mobility. Dysfunction of this signal 
transduction has been reported in other neurodegenerative diseases, 
including amyotrophic lateral sclerosis (ALS) and spinal muscular at-
rophy (SMA) (Li et al., 2018; Ohno et al., 2017). Therefore, we postulate 
that it might be relevant for the amyotrophy seen in a significant pro-
portion of MJD patients as well as in animal models of the disease (Sara 
Duarte-Silva, personal communication). 
The network analysis considering ATXN3 and the nine genes pro-
vided by genotype-phenotype correlations generated a network of 200 
genes; pathway-enrichment analysis, using these genes as input dataset, 
revealed the highest enrichment of the Bcl-2 associated athanogene 
(BAG) signaling pathway and the protein ubiquitination pathway. The 
emergence of the protein ubiquitination pathway is consistent with the 
physiological role of ataxin-3 as deubiquitinating enzyme (Costa, and do 
C, Paulson HL., 2012). The BAG protein family has been associated with 
neurodegenerative diseases, including MJD (reviewed in Che et al. 
(2015); Qin et al. (2016)). Playing a key role in protein degradation, 
BAG proteins, namely BAG2 and BAG5, modify mutated ataxin-3 
toxicity by regulating its stability (Che et al., 2015). 
Genotype-phenotype correlations showed that variants in ACTG1, 
CFAP57 and DIDO1 have consistent effects in delaying AO in MJD. 
ACTG1 encodes for the actin cytoplasmic 2 protein, an actin monomer 
(G-actin), which composes the actin cytoskeleton after polymerization 
(reviewed in Eira et al. (2016)). Alterations in the actin regulatory 
machinery have been suggested in a Drosophila MJD model (Lee et al., 
2011; Vu et al., 2018) and actin cytoskeleton disorganization was seen 
upon ATXN3 silencing or polyQ expansion in cultured cells (Rodrigues 
et al., 2010; Neves-Carvalho et al., 2015). Data from an RNA-seq 
experiment using six samples from cerebellum of MJD patients and 
controls showed that mRNA levels of ACTG1 were decreased in MJD 
patients compared to controls (q-value<0.05; 43). In healthy popula-
tion, ACTG1 levels have been described as highly expressed in cere-
bellum as well as in other brain areas, not showing significant tissue- 
specific differences (GTEx Consortium, 2013). 
Our network analysis further revealed a direct interaction between 
ACTG1 and APOE (an ATXN3 interactor), a modifier gene previously 
described by us and subsequently replicated in a Chinese cohort (Bet-
tencourt et al., 2011; Peng et al., 2014). Another link between ACTG1 
and ATXN3 is its direct interaction with PRKN (encoding parkin). Parkin 
is a E3 ubiquitin ligase, commonly associated with inherited and spo-
radic Parkinson’s disease (reviewed in Dawson and Dawson (2010)). 
Fig. 3. Interaction network showing the relationship between ATXN3 and the candidate modifier genes validated by genotype-phenotype correlations. Network 
analysis was performed in the IPA software, using the Path Explorer tool. The relationship between the modifier genes and ATXN3 were highlighted, concerning (1) 
the absence of intermediate molecules (direct connection) – red, (2) the presence of a single intermediate molecule – green and (3) two intermediate molecules – blue. 
Direct interactors of ATXN3 were highlighted in orange. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of 
this article.) 
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Parkin is deubiquitinated by ataxin-3 (Durcan et al., 2011); mutant (but 
not wild-type) ataxin-3 promotes clearance of parkin via autophagy, 
suggesting that increased turnover of parkin may contribute to the MJD 
pathogenesis (Durcan et al., 2011; Durcan and Fon, 2013). The synon-
ymous variant in ACTG1 implied an alteration of the auxiliary splicing 
sequences; according to in silico predictions its presence should signif-
icantly alter the ESE/ESS (exonic splicing enhancer or silencer) motifs 
ratio (data not shown). The role of splicing defects in human disease is 
rapidly emerging nowadays; gain or loss of enhancers and silencer se-
quences can lead to the alternative inclusion of exons, and this type of 
splicing defect has been associated with neurodegenerative diseases, 
namely with frontotemporal dementia and Parkinsonism linked to 
chromosome 17 or spinal muscular atrophy (Daguenet et al., 2015). 
CFAP57 variant also implied a consistent delaying of disease onset; 
this gene encodes for cilia- and flagella-associated protein 57, a member 
of the WD40 family of proteins, frequently acting as protein interaction 
scaffolds to form functional complexes through their WDR domain, in 
essential cellular processes (Zou et al., 2016). In healthy population, 
CFAP57 seems to be similarly expressed in vulnerable and non- 
vulnerable MJD brain areas (GTEx Consortium, 2013). Moreover, 
levels of this gene were similar in the cerebellum of MJD patients and 
controls (Haas et al., n.d.). mRNA levels of ATG16L2, a gene which 
encodes also a protein presenting a WD40 domain, were described to be 
reduced in blood cells of MJD subjects, including preclinical carriers, 
when compared to age- and sex-matched controls (Ana F. Ferreira, 
personal communication). Intriguing, the loss of the WDR domain in 
LRRK2, another protein of the WD40 family, was block neurotoxicity of 
multiple LRRK2 Parkinson’s disease causative variants (Schapira et al., 
2017). Although alterations on splicing signals could be predicted for 
the intronic variant in CFAP57, this should not lead to a significant 
impact on splicing (data not shown). 
Variants in DIDO1 were also associated to a delaying effect on MJD 
onset. DIDO1 encodes for death-inducer obliterator 1 (DIO-1) protein, 
triggering apoptosis through up-regulation of procaspase 3 and 9 (Gar-
cía-Domingo et al., 2003). In healthy population, DIDO1 is slightly more 
expressed in cerebellum compared to other vulnerable (brainstem) and 
non-vulnerable MJD brain areas (GTEx Consortium, 2013). Interesting, 
a tendency for an up-regulation of DIDO1 levels in the cerebellum of 
MJD patients compared to controls was observed (p-value = 0.018 and 
q-value<0.15; 43). Of note, mutant ataxin-3 has been associated with 
mitochondrial apoptotic pathway, through activation of caspase-3 and 
caspase-9 (Chou et al., 2006). DIDO1/CASP3 and ATXN3/CASP3 re-
lationships were also identified in our network analysis. This also 
highlighted a protein-protein interaction between DIDO1 and APP 
(amyloid precursor protein); APP mRNA level was shown to be upre-
gulated in CSM14.1 rat cell lines stably expressing human full-length 
expanded ataxin-3 (Evert et al., 2001). Moreover, several Aβ-immuno-
reactive deposits were observed in human MJD pons compared to con-
trols (Evert et al., 2001). The impact of the two DIDO1 missense variants 
(V1 and V2) on protein structure/function was predicted to be non- 
pathogenic (benign/tolerant). However, by splicing predictions, the 
alternative allele of DIDO1-V2 implied the activation of a cryptic donor 
site, and therefore, potentially leading to alterations of splicing (data not 
shown). 
A consistent role of PARD3, NFKB1, CHD5, DLGAP2, ITGB1 and 
CERS4 as genetic modifiers in the different MJD cohorts could not be 
observed in this study; the statistical power, however, should not be 
pointed out as the reason to explain this lack of consistency of the var-
iant’s effects on AO. For example, in the Brazilian cohort, the DLGAP2 
variant was associated with an earlier onset, explaining 10% of AO 
variance; a genotype-phenotype correlation study with ~50 patients (25 
per group) would be able to detect an effect size of 0.5 in AO (supple-
mentary Fig. 2). This means that the modifier effect of DLGAP2 on AO 
should have been found at least in the Portuguese cohort (N = 175). 
Although previous evidence about the role of genetic modifiers in 
MJD was grounded on single gene effects, contribution of a single 
modifier to the phenotype is usually minor, and can be masked by 
environmental or population effects, as well as by the individual genetic 
background. Complex interactions between the primary disease-causing 
gene and a (yet) undetermined number of other modifiers playing a role 
in a common cell mechanism, as well as a variable combination of 
multiple gene variants among patients may determine the phenotypic 
outcome of MJD. As consequence, the effect on AO of variants in PARD3, 
CHD5, DLGAP2, ITGB1, NFKB1 and CERS4 (the last two in interaction 
with CAGE), whose effects were not found across the several cohorts, 
may be population-specific but not necessarily without value. Difference 
in frequency of the ATXN3 expansion size, in combination with variable 
allelic frequencies of a variety of modifiers, might be the most important 
factor to explain non-replication of modifying effects across cohorts. 
Greene and colleagues showed that alterations in allele frequency at one 
interacting locus may decrease power to detect a main effect at another 
locus: changes in minor allele frequency (MAF) of less than 0.1 may 
imply a loss of power from 80% to 20% to replicate the main effect 
(Greene et al., 2009). In this perspective, patient stratification by CAGE 
in different cohorts has consistently been reported in MJD (Raposo et al., 
2015; de Mattos et al., 2019; Tezenas du Montcel et al., 2014), also 
observed in this study; Brazilian patients showed larger expansions more 
frequently than Portuguese patients, or patients from the multi-ethnic 
cohort (Suppl. Table 8). Of note, the identification of epistatic effects 
is challenging in MJD, as it is in other diseases caused by dynamic 
mutations. The large diversity of CAGE alleles in interaction with mul-
tiple modifiers results in a small number of patients in each group to 
allow further statistical comparisons, which has implications to reach 
the necessary power, in a rare disease such as MJD. 
5. Conclusions 
In summary, we propose novel MJD-modifying genes and pathways 
for further investigation as new disease-modifying targets. Unveiling 
mechanisms of novel MJD-modifying pathways may be a novel attrac-
tive avenue to explore pharmacologically than testing single modifier 
genes, a clear limitation of candidate gene studies. Characterization of 
the complex contribution of these genes to the MJD phenotype should 
help improving more individualized disease management and prognosis. 
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